PropertyValue
?:abstract
  • In a deal worth up to $362 million, Vir Biotechnology has tapped Samsung Biologics to provide commercial-scale production of a monoclonal antibody against the novel coronavirus Vir hopes to begin Phase II clinical trials in the next 3–5 months “We are taking proactive steps to reserve large-scale manufacturing capacity to be ready to move quickly with any of our antibody candidates that prove to be clinically safe and effective,” says Vir CEO George Scangos Vir has a similar production deal with WuXi Biologics
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Vir taps Samsung for coronavirus candidate
?:type
?:who_covidence_id
  • #100621
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/r35o89jy>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/r35o89jy>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all